Nebenwirkungen · Rasilez
Rasilez 150 mg film-coated tablets Rasilez 300 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 8
HOS-208772 · Präparat HOS-154177
Aliskiren has been evaluated for safety in more than 7,800 patients, including over 2,300 treated for over 6 months, and more than 1,200 for over 1 year. The adverse reactions are ranked under heading of frequency, the most frequent first, using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from the available data).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T02:00:00Z · SHA-256 4518ee1f6936dd9da7c06dbb3fa8bed38b206400f5cb767391af486f27614e43 · Passage 49234a70ff5fa08d9fdbba8a4d93b88b4abe5f0db9423a9456b8146f6c29dc09 · Zeichen 301–763 im Abschnitt